The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

NCT01472640 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can improve heart function in adults with chronic heart failure, with or without type 2 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 240 people

Who can join Ages 30–85 · all sexes

Timeline Started 2011-11 · est. completion 2015-10

Where 4 sites · Denmark

What this study is testing ClinicalTrials.gov NCT01472640 ↗

Description as written by the study sponsor.

Type 2 diabetes (T2D) is a major risk factor of chronic heart failure (CHF). Glycemic control in patients with the combination of T2D and CHF is complicated and the currently available treatments have proven to be inadequate in clinical trials. Objectives To investigate the effect of Liraglutide compared to placebo on left ventricular ejection fraction (LVEF) in CHF patients with and without T2D. Multicenter, randomized, double blind study of 240 patients with documented systolic CHF (50% with T2DM) will be randomised. The effect of Liraglutide on left ventricular systolic and diastolic function will be evaluated by advanced echocardiography Primary outcome parameter is change in LVEF from visit 1 to week 24.

Treatments tested

liraglutide also known as Victoza Drug

1.8 mg sc QOD
placebo Drug

1 U sc QOD

Main thing measured	Change in Left ventricular function from visit 1 to week 24, measured by Ecco
Sponsor	Flyvbjerg, Allan, DMSc
Conditions studied	Hyperglycemia, Chronic Heart Failure
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01472640 ↗